US EditionPublished • loading... • Updated
Pfizer Is Reviving Its Chance in the Obesity Market by Buying the Biotech Metera
Summary by Le Monde
2 Articles
2 Articles
The U.S. pharmaceutical giant had failed to develop in-house a drug candidate that could compete with the mastodons in the sector.
·Paris, France
Read Full Article
The CEO of Pfizer, Albert Bourla, at the economic meetings of Davos (Switzerland), on January 23, 2025. FABRICE COFFRINI/AFP Pfizer did not say his last word in the field, very coveted, of weight loss remedies. After having failed in recent years to develop a candidate-drug in-house, the pharmaceutical laboratory recovers in the race for treatments against obesity by putting its hands on the biotech Metera. L'industriel New York announced, Monda…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
